文献速递胸部肿瘤

初治晚期非小细胞肺癌患者一线液体二代测序:台湾医疗体系中的一项前瞻性随机研究

Upfront liquid next-generation sequencing in treatment-naïve advanced non-small cell lung cancer patients: A prospective randomised study in the Taiwanese health system.
PubMed 文献 · Eur J Cancer · 2023-08-28

这项前瞻性随机研究纳入180例疑似晚期非小细胞肺癌患者,全部在首次就诊时接受血液液体二代测序(NGS)并行标准组织诊断与分型;组织确诊的63例(A组)和59例(B组)中,B组在组织确诊后尽快获知NGS结果,开始全身治疗的中位时间B组20天、A组28天;两组客观缓解率和无进展生存期无显著差异,液体NGS与组织检测高度一致,在42.6%(20/47)组织阴性病例中检出驱动突变。

要点

  • 疑似晚期NSCLC首诊即行液体NGS,可缩短开始全身治疗时间(B组20天 vs A组28天)。
  • 液体NGS与组织检测高度一致,在42.6%(20/47)组织阴性病例中检出驱动突变。
  • 两组客观缓解率与无进展生存期无显著差异。

核心结论

  • 对疑似晚期NSCLC患者在首次就诊时行液体NGS可识别更多适合靶向治疗的患者,并缩短开始治疗时间。

研究设计与样本

  • 前瞻性随机研究,纳入180例疑似晚期NSCLC患者,全部在首次就诊时接受血液液体NGS并接受标准组织学诊断与组织分型。
  • 组织确诊的晚期NSCLC患者中,A组63例在组织分型后获知NGS结果,B组59例在组织学确诊后尽快获知NGS结果。
  • 主要终点为开始全身治疗的时间,次要终点包括生物标志物检出率、客观缓解率(ORR)和无进展生存期(PFS)。

主要发现

  • A组和B组分别有63例和59例确诊为晚期NSCLC并纳入分析,多数为腺癌(A组77.8%,B组79.7%)。
  • 两组EGFR突变患病率相近(A组57.1%,B组56.6%),其他驱动基因改变少见。
  • 开始治疗的中位时间B组为20天,短于A组的28天。
  • 两组ORR和PFS无显著差异。
  • 液体NGS与组织检测高度一致,并在42.6%(20/47)的组织阴性病例中检出驱动突变。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Next-generation sequencing (NGS) of plasma cell-free DNA identifies driver mutations in advanced non-small cell lung cancer (NSCLC) and may complement routine molecular evaluation. The utility of liquid NGS at the start of tumour workup is undetermined. METHODS: This is a randomised study of patients with suspected advanced NSCLC. All patients received blood liquid NGS testing at their first clinic visit and underwent standard histological diagnosis and tissue genotyping, encompassing polymerase chain reaction based methods for EGFR mutation, immunohistochemical (IHC) staining for ALK fusion and BRAF V600E mutation, and an IHC screening followed by confirmation using fluorescence in situ hybridization confirmation for ROS1 fusion. They were then randomly assigned to receive NGS results either after tissue genotyping (Group A) or as soon as possible after histological diagnosis of advanced NSCLC (Group B). The study measured time to start of systemic treatment as the primary endpoint and secondary endpoints included biomarker discovery rate, objective response rate (ORR), and progression-free survival (PFS). RESULTS: This study enroled 180 patients with suspected advanced NSCLC, randomised into two groups. 63 patients in Group A and 59 in Group B with advanced NSCLC were confirmed as advanced NSCLC and analysed. Most had adenocarcinoma (Group A: 77.8%, Group B: 79.7%). The prevalence of EGFR mutations in the two groups was similar (Group A: 57.1%; Group B: 56.6%). Other driver alterations were rare. The median time to treatment was shorter in Group B (20 days) than in Group A (28 days). ORR and PFS did not differ between groups significantly. Liquid NGS had high concordance with tissue testing and identified driver mutations in 42.6% (20/47) of tissue-negative cases. CONCLUSION: Performing liquid NGS at the initial clinic visit for suspected advanced NSCLC identifies more patients suitable for targeted therapies and shortens time to the start of treatment.

来源:Eur J Cancer,查看原文。版权归原作者所有。

引用

  1. Yang CY, Shih JY, Liao WY, et al. Upfront liquid next-generation sequencing in treatment-naïve advanced non-small cell lung cancer patients: A prospective randomised study in the Taiwanese health system. Eur J Cancer. 2023. PMID: 37722270. doi:10.1016/j.ejca.2023.113310

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。